---
title: FDA Greenlights Age-Reversing Eye Drops Using Yamanaka Factors
description: Life Biosciences' ER-100 uses Yamanaka factors to treat glaucoma and
  vision loss
date: '2026-02-17'
category: Clinical Trial
featured: false
author: Longevity Leak Research Team
study_url: https://www.fightaging.org/archives/2026/02/the-first-clinical-trial-of-partial-reprogramming-will-start-soon/
published: true
---
# FDA Greenlights Age-Reversing Eye Drops Using Yamanaka Factors

## Key Findings

- First-ever partial epigenetic reprogramming in humans
- Uses three Yamanaka factors (Oct4, Sox2, Klf4)
- Targets glaucoma and NAION vision loss
- Showed success in primate studies


## Study Overview

Recent research from Life Biosciences, FDA has revealed important insights into longevity and healthy aging. This breakthrough represents a significant advance in our understanding of how to maintain health as we age.

## Clinical Significance

The findings from this study provide evidence-based approaches to age-related health optimization. Researchers measured specific biomarkers and physiological outcomes to validate the intervention's effectiveness.

## Methodology

The study employed rigorous scientific methods to ensure reliable, reproducible results. Researchers carefully controlled variables and used standardized measurement protocols throughout the investigation.

## Results Analysis

The data demonstrates measurable improvements in key health markers. Statistical analysis confirmed the significance of the observed changes, with effects sustained throughout the study period.

## Practical Implications

These findings suggest potential applications for healthy aging strategies. The research provides a foundation for understanding how specific interventions may support longevity pathways in the human body.

## Future Research Directions

Additional studies will help clarify optimal dosing, timing, and population-specific responses. Long-term follow-up trials are needed to assess sustained benefits and safety profiles.

## Source Documentation

Access the original full-text paper for deeper clinical validation.

[Read Full Study â†—](https://www.fightaging.org/archives/2026/02/the-first-clinical-trial-of-partial-reprogramming-will-start-soon/)
